Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Vitro Diagnostics has signed an agreement to form a broad-ranging strategic alliance with Italy-headquartered assisted reproduction company BioCare Europe.
Subscribe to our email newsletter
The partnership includes various agreements with regard to commercialization of Vitro’s stem cell lines for use in R&D and cross licenses to fertility drug technology and products owned by both Vitro and BioCare.
Initially, the agreement provides BioCare with distribution rights to the current Vitrocell product line, an additional human pancreatic stem cell line that is in advanced development and related products within the European territory.
Separately, Vitro will also offer BioCare an option to commercialize Vitro’s fertility drug Vitropin and subsequent forms in the same territories. BioCare will also provide Vitro exclusive licensing rights to BioCare’s patent-pending technology for the production of select chimeric hormone products for the entire North American territory.
Dr James Posillico, president and CEO of Vitro, said, “We are pleased to announce the beginning of our partnership with BioCare which offers mutual advantages by targeting the distribution of each company’s products to major markets in North America and Europe.”